Deals
Cardinal Health to Buy Harvard Drug Group for $1.12 Billion
This article is for subscribers only.
Cardinal Health Inc. said it will buy the Harvard Drug Group from Court Square Capital Partners for $1.12 billion to increase its distribution of generic drugs.
Cardinal Health will fund the acquisition with cash and new debt, the Dublin, Ohio-based company said Friday in a statement. The purchase will add more than 15 cents to earnings per share from continuing operations in fiscal-year 2016, it said.